# PANVAC™-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing Regimen

> **NCT00088660** · PHASE3 · UNKNOWN · sponsor: **Therion Biologics Corporation** · enrollment: 250 (—)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** PANVAC™-VF

## Key facts

- **NCT ID:** NCT00088660
- **Lead sponsor:** Therion Biologics Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2004-06
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 250 (—)
- **Last updated:** 2006-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00088660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00088660, "PANVAC™-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing Regimen". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00088660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*